Information Provided By:
Fly News Breaks for December 11, 2019
AGIO
Dec 11, 2019 | 05:20 EDT
Piper Jaffray analyst Tyler Van Buren says Agios Pharmaceuticals remains a favorite name ahead of the company's beta thalassemia and sickle cell disease updates in the first half of 2020. The disclosure at ASH that seven out of the eight initial mitapivat beta thalassemia patients responded was by far the biggest update during the conference, Van Buren tells investors in a research note. During the first half of next year, Agios could see initial sickle cell data from patients treated with mitapivat, which represents an opportunity that is five-fold larger, adds the analyst. He recommends that investors continue to own Agios shares through next year and keeps an Overweight rating on the name.
News For AGIO From the Last 2 Days
There are no results for your query AGIO